Novo Nordisk $NVO – My largest equity position and why I hold it
Novo Nordisk ($NVO) is my largest equity position, making up 11.5% of the portfolio value with an unrealized gain of 31.29%. As a leader in diabetes and obesity treatment (e.g., Ozempic and Wegovy) it’s on an upward trend – it rose 9.12% on January 16, 2026, closing at $62.33. I plan to hold it long term because of its growth potential.
Strategy: Target price $65. If it exceeds $71.50, I’ll set a trailing stop loss starting at $65 to lock in gains and benefit from further upside.
Is it wise? Yes, it fits a trend-following approach with risk management.
Alternatives: Partial sales to rebalance the portfolio.
Positives:
High demand for GLP-1 drugs and for an oral form of Wegovy. Strong EPS and ROE growth creates real company value. Resilient healthcare sector.
Negatives:
High profits attract competition from generics manufacturers. Regulatory/legal issues can significantly increase volatility.
Your thoughts on $NVO – hold with a TSL or sell some off?
Bulios Black
This user has access to exclusive content, tools and features of the Bulios platform thanks to their subscription.
For me, holding with a trailing stop loss makes sense. The trend is strong and fundamentals still support the story. I’d consider a partial sell only for portfolio rebalancing, not because the NVO thesis is breaking. Competition and regulation are real risks, but that’s fairly standard in this sector.
Bulios Black
This user has access to exclusive content, tools and features of the Bulios platform thanks to their subscription.
You timed that purchase well, and I think you’re one of the few who aren’t at a loss 😂. I’m still holding the shares and I won’t sell until it gets above $100.
I wouldn’t get rid of it. I own it too and I think the oral variant they launched on January 9, 2026, and the fact that it’s widely available will bring them a lot of customers. Many people have trouble giving themselves injections. For Q1 they’re still the only ones. Competitor $LLY will bring a pill version to market in April.
I own both companies and I’d like to proceed as follows
- wait for the development of $NVO shares (65–70 USD seems low to me), which will benefit from a temporary market advantage
- I therefore expect a decline in $LLY, an outflow of investors to the competitor
- from selling part of the $NVO position I would then buy more $LLY
Each company has its own version, but Lilly’s variant is more effective (two-component). However, Novo also has a two-component drug that is currently in phase 3 clinical trials and should be more effective, i.e. weight loss >20%. Current preparations are around 15%.
There’s one more factor: the exclusivity period for the injectable weight-loss drugs will expire and generic manufacturers are lining up to target them, so that portion of profits will disappear for both companies.